Capromab (ProstaScint Kit for the preparation of In-111capromab pendetide, murine) is an MAb (murine IgG1 κ)that derives from an initial sensitization with a glycoproteinexpressed by prostate epithelium known as prostate surfacemembrane antigen (PSMA). The MAb recognizes PSMAspecifically and thus is specific for prostate adenocarcinomas.The drug is used in newly diagnosed patients withproven prostate cancer who are at high risk for pelvic lymphmetastasis. PSMA has been found in many primary andmetastatic prostate cancer lesions. The cytoplasmic domainmarker 7E11-C5.3 reacts with more than 95% of adenocarcinomasevaluated.
To join the indium-111 to the antibody, a linker-chelatoris used. This moiety is glycyltyrosyl-(N-ethylenetriaminepentaaceticacid)-lysine HCl.
